Approximately 2030% of patients on GLP-1 receptor agonists report diminished appetite suppression after 612 months of continuous use
The "sun risk" is therefore less about which specific drug you're on, and more about the *severity* of the GI side effects you personally experience and your individual hydration status
Obesity Pharmacotherapy: Current Perspectives and Future Directions, Misra M., Journal (Current Cardiology Reviews, Volume 9, Issue 1, February 2013, Pages 3354)
Tirzepatide demonstrated approximately 5-fold lower affinity at the GLP-1 receptor compared to native GLP-1, and 20-fold lower potency in cellular signaling compared to semaglutide
However, private insurers administer Part D plans in line with Medicare regulations and may choose their own formulary of approved drugs
M.BusquetsS.StemmlerB.Lpez-SorianoF